Neurogene CEO Details NGN-401 Rett Trial, FDA Alignment, and Key 2026 Catalysts at Conference

Neurogene (NASDAQ: NGNE) CEO and founder Rachel McMinn outlined the company's progress toward a potential commercial launch for its lead gene therapy candidate, NGN-401, during a fireside chat focused on Rett syndrome, regulatory alignment, trial design, and upcoming catalysts. Company focus and lead program McMinn described Neurogene as a genetic medicines company developing treatments for "devastating